Clinical trials are fundamental to the development of new treatments for cancer, but annual accrual to studies worldwide is low, at an estimated at three to five percent.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.